Top Line: Can concurrent high dose cisplatin be given over several days every 3 weeks to reduce toxicity in patients with head and neck cancer?
The Study: Cisplatin at a dose of 100 mg/m2 given every 3 weeks is considered the standard concurrent chemotherapy regimen during head and neck cancer radiation. However, this regimen can have significant toxicity and many patients aren’t able to receive a third cycle. Studies have shown that the cumulative cisplatin dose is associated with survival outcomes in head and neck cancer. A randomized Japanese trial found that weekly cisplatin at a dose of 40 mg/m2 was noninferior to the standard regimen in patients receiving adjuvant treatment. This randomized phase 2 trial took the approach of fractionating q3wk cisplatin. What this means is that instead of giving the full 100 mg/m2 during one infusion, that dose was split over a 4 day period (25 mg/m2 per day). It randomized 124 patients receiving definitive, concurrent CRT with 100 mg/m2 cisplatin every 3 weeks to standard 1-day infusion or the 4-day fractionated infusion with the goal of increasing the cumulative cisplatin dose. Median cumulative cisplatin dose didn’t quite exceed the threshold for significance with fractionated infusion (291 mg/m2 v 275 mg/m2, p=0.054). However, a higher proportion of patients received the full third cycle with fractionated infusion (81% v 64%), and the rate of grade 3-4 toxicity was significantly lower (10% v 17%). There was no difference in locoregional failure at 48 months.
TBL: This randomized phase 2 trial found that using an alternative 4-day infusion of high dose concurrent cisplatin may increase the proportion of patients receiving a full 3 cycles while also reducing toxicity. | Borel, Radiother Oncol 2024
The Study: Cisplatin at a dose of 100 mg/m2 given every 3 weeks is considered the standard concurrent chemotherapy regimen during head and neck cancer radiation. However, this regimen can have significant toxicity and many patients aren’t able to receive a third cycle. Studies have shown that the cumulative cisplatin dose is associated with survival outcomes in head and neck cancer. A randomized Japanese trial found that weekly cisplatin at a dose of 40 mg/m2 was noninferior to the standard regimen in patients receiving adjuvant treatment. This randomized phase 2 trial took the approach of fractionating q3wk cisplatin. What this means is that instead of giving the full 100 mg/m2 during one infusion, that dose was split over a 4 day period (25 mg/m2 per day). It randomized 124 patients receiving definitive, concurrent CRT with 100 mg/m2 cisplatin every 3 weeks to standard 1-day infusion or the 4-day fractionated infusion with the goal of increasing the cumulative cisplatin dose. Median cumulative cisplatin dose didn’t quite exceed the threshold for significance with fractionated infusion (291 mg/m2 v 275 mg/m2, p=0.054). However, a higher proportion of patients received the full third cycle with fractionated infusion (81% v 64%), and the rate of grade 3-4 toxicity was significantly lower (10% v 17%). There was no difference in locoregional failure at 48 months.
TBL: This randomized phase 2 trial found that using an alternative 4-day infusion of high dose concurrent cisplatin may increase the proportion of patients receiving a full 3 cycles while also reducing toxicity. | Borel, Radiother Oncol 2024

